JW HOLDINGS CORPORATION
Financials
Valuation Metrics
JW HOLDINGS CORPORATION's Market Cap is ₩2809B. At end of 2025 it was ₩2654B. Ranked #658 of 2,436 in KR market (top 27%), #391 of 787 on KOSPI (top 50%), #74 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 32%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 280.91B KRW | KR#658/2,436 Sec#74/234 |
| Revenue | 973.26B KRW | KR#411/2,436 Sec#14/234 |
| Net Income | 125.85B KRW | KR#189/2,436 Sec#11/234 |
| Total Assets | 1.27T KRW | KR#408/2,436 Sec#21/234 |
| Net Assets | 605.85B KRW | KR#425/2,436 Sec#28/234 |
| Employees | 139 | KR#1,377/2,436 Sec#110/234 |
| Value | ||
| P/E | 2.23x | KR#63/2,436 Sec#1/234 |
| P/B | 0.46x | KR#726/2,436 Sec#25/234 |
| PEG | 0.06x | KR#308/2,436 Sec#15/234 |
| P/S | 0.29x | KR#577/2,436 Sec#13/234 |
| EV/EBITDA | 3.15x | KR#91/2,436 Sec#1/234 |
| FCF Yield | 47.80% | KR#90/2,436 Sec#1/234 |
| Profitability | ||
| ROE | 20.77% | KR#119/2,436 Sec#9/234 |
| ROA | 9.94% | KR#198/2,436 Sec#15/234 |
| Op. Margin | 18.25% | KR#180/2,436 Sec#19/234 |
| Revenue Growth | 1.54% | KR#1,339/2,436 Sec#123/234 |
| Earnings Growth | 35.18% | KR#656/2,436 Sec#41/234 |
| Financial Health | ||
| Debt Ratio | 208.98% | KR#1,772/2,436 Sec#193/234 |
| Total Debt | 344.15B KRW | KR#364/2,436 Sec#18/234 |
| FCF | 134.28B KRW | KR#146/2,436 Sec#7/234 |
| Cash | 64.76B KRW | KR#626/2,436 Sec#30/234 |
| Current Ratio | 0.73x | KR#2,107/2,436 Sec#200/234 |
| Net Debt/EBITDA | 1.57x | KR#855/2,436 Sec#60/234 |
| Dividend | ||
| Div. Yield | 5.76% | KR#205/2,436 Sec#7/234 |
| Div. Growth | 86.96% | KR#151/2,436 Sec#3/234 |
| Performance | ||
| 1Y Return | 8.73% | KR#554/2,436 Sec#44/234 |
| 1M Return | -1.68% | KR#1,065/2,436 Sec#103/234 |
| From 52W High | -15.46% | KR#112/2,436 Sec#5/234 |
| 1Y MDD | -23.55% | KR#86/2,436 Sec#4/234 |
| Trading | ||
| Volume | 33,405 shares | KR#1,590/2,436 Sec#156/234 |
| Foreign Own. | 3.41% | KR#968/2,436 Sec#95/234 |
| Per Share | ||
| EPS | 934 KRW | KR#648/2,436 Sec#44/234 |
| BPS | 3,929 KRW | KR#1,623/2,436 Sec#124/234 |
Company Info
Established in 2007 as a holding company through a human spin-off of the investment and overseas business divisions from JW Pharmaceutical, the company changed its name to JW Holdings in 2010. As of the end of the current quarter, it has six subsidiaries, including JW Pharmaceutical, engaged in pharmaceutical manufacturing and sales, R&D, and medical device manufacturing and sales. Through JW Pharmaceutical, the company has entered global Phase 3 trials for the gout treatment URC102 and received clinical Phase 1 approval for the STAT3 targeted anticancer drug JW2286, driving innovative new drug development. JW Holdings is headquartered in Gwacheon, Gyeonggi-do.